[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628489":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":50,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":77,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Genotype-guided Dosing Group","EXPERIMENTAL","All participants will receive 6-MP maintenance therapy with dosage adjustments based on their NUDT15 and TPMT genotype status.",[13],"Drug: NUDT15\u002FTPMT genotype-guided 6-MP dosing",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","NUDT15\u002FTPMT genotype-guided 6-MP dosing","Initial dosage of 6-Mercaptopurine (6-MP) is stratified based on NUDT15 and TPMT genotypes:\n\nNormal metabolizers: 100% standard dose (50-75 mg\u002Fm\\^2\u002Fd). Intermediate metabolizers: 30-80% of the recommended dose. Poor metabolizers: 10-30% of the recommended dose. Subsequent dosage adjustments are made based on toxicity monitoring and therapeutic drug monitoring (TDM) of 6-TGN and 6-MMP levels.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Tian Xia, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"tian xia, MD","CONTACT","+86 15267035696","xiatiansky2013@163.com",[32],{"facility":5,"status":20,"city":33,"state":34,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Hangzhou","Zhejiang","China","CN",{"type":38,"coordinates":39},"Point",[40,41],120.16142,30.29365,{"lat":41,"lon":40},[44],{"name":45,"role":28,"phone":46,"phoneExt":20,"email":30},"Tian Xia, PhD","86-15267035696",{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"xiatian","Attending Physician",[51],{"name":52,"class":6},"Zhejiang University","100628489",false,"NCT07462299","NUDT15\u002FTPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy","A Prospective Study of NUDT15\u002FTPMT Multi-gene Combined Guidance on 6-MP Dosage During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\nDiagnosed with ALL and scheduled for maintenance therapy. Plan to receive oral 6-MP. NUDT15 and TPMT genotyping results available. Baseline liver and kidney function within acceptable limits (ALT\u002FAST ≤ 2.5xULN, etc.).\n\nSigned informed consent. -\n\nExclusion Criteria:\n\nDown syndrome. Relapsed\u002Frefractory disease before maintenance. Prior hematopoietic stem cell transplantation. Severe organ dysfunction or uncontrolled infection.\n\n\\-","ALL","1 Year","18 Years",{"count":63,"type":64},110,"ESTIMATED","INTERVENTIONAL",[67],"NA","This is a prospective, single-center clinical study to evaluate the safety and efficacy of a personalized 6-mercaptopurine (6-MP) dosing strategy guided by NUDT15 and TPMT genotypes in children with Acute Lymphoblastic Leukemia (ALL) during maintenance therapy. The study compares this gene-guided strategy with historical controls to assess if it reduces the incidence of Grade ≥3 neutropenia and infection events.",[70],"Childhood Acute Lymphoblastic Leukemia",[72,73,74,75,76],"NUDT15","TPMT","6-MP","Pharmacogenetics","Maintenance Therapy","NOT_YET_RECRUITING","2026-03-05",{"date":80,"type":81},"2026-03-10","ACTUAL",{"date":83,"type":64},"2026-02-20",{"date":85,"type":64},"2028-12-31",{"name":5,"class":6},1]